RhumbLine Advisers
NERV icon

RhumbLine Advisers’s Minerva Neurosciences NERV Stock Holding History

RhumbLine Advisers’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
+29,867
New +$162K ﹤0.01% 3358
2021
Q2 		– Sell
-5,219
Closed -$122K – 3069
2021
Q1 		$122K Hold
5,219
– – ﹤0.01% 2913
2020
Q4 		$98K Buy
5,219
+337
+7% +$8.49K ﹤0.01% 2969
2020
Q3 		$124K Sell
4,882
-564
-10% -$15.2K ﹤0.01% 2827
2020
Q2 		$157K Buy
5,446
+238
+5% +$14K ﹤0.01% 2851
2020
Q1 		$251K Hold
5,208
– – ﹤0.01% 2482
2019
Q4 		$296K Buy
5,208
+130
+3% +$5.73K ﹤0.01% 2594
2019
Q3 		$315K Buy
5,078
+45
+0.9% +$2.55K ﹤0.01% 2556
2019
Q2 		$227K Buy
5,033
+30
+0.6% +$1.5K ﹤0.01% 2739
2019
Q1 		$315K Sell
5,003
-111
-2% -$6.67K ﹤0.01% 2523
2018
Q4 		$276K Buy
5,114
+1,667
+48% +$122K ﹤0.01% 2581
2018
Q3 		$346K Sell
3,447
-210
-6% -$15.8K ﹤0.01% 2448
2018
Q2 		$241K Buy
3,657
+760
+26% +$46.2K ﹤0.01% 2646
2018
Q1 		$145K Sell
2,897
-21
-0.7% -$1.01K ﹤0.01% 2677
2017
Q4 		$141K Sell
2,918
-554
-16% -$27.5K ﹤0.01% 2723
2017
Q3 		$211K Buy
3,472
+87
+3% +$4.99K ﹤0.01% 2708
2017
Q2 		$240K Buy
3,385
+893
+36% +$57.8K ﹤0.01% 2668
2017
Q1 		$161K Buy
2,492
+99
+4% +$7.69K ﹤0.01% 2707
2016
Q4 		$225K Buy
2,393
+241
+11% +$24.6K ﹤0.01% 2628
2016
Q3 		$243K Buy
2,152
+197
+10% +$19.1K ﹤0.01% 2585
2016
Q2 		$160K Buy
+1,955
New +$124K ﹤0.01% 2821

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's NERV Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Minerva Neurosciences (NERV) in Q2 2026: 29,867 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #3358 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in NERV as recently as Q1 2021.

RhumbLine Advisers first reported a position in NERV in Q2 2016 and has held it in 21 quarters since. The position peaked at $346K in Q3 2018. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • RhumbLine Advisers held 29,867 shares of Minerva Neurosciences worth $166K as of Q2 2026.
  • Minerva Neurosciences was a new RhumbLine Advisers position in Q2 2026.
  • Minerva Neurosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3358 holding.
  • RhumbLine Advisers first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 21 quarters since.
  • RhumbLine Advisers's Minerva Neurosciences position peaked at $346K in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.